ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
100,579.08
-1.67%
S&P 500
5,975.38
0.00%
Dow Jones
42,706.56
0.00%
US Dollar vs Yen
157.6745
-0.05%
Brent Oil
76.515
0.53%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ

  6. Celldex Therapeutics Inc (CLDX) 銘柄情報

Celldex Therapeutics Inc

Celldex Therapeutics Inc (CLDX)

NASDAQ
26.58
-0.23
(-0.86%)
終了 1月7日 6:00AM
15分遅延
27.20
0.62
( 2.33% )
プレマーケット: 10:39PM
15分遅延

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

主要統計と詳細

通貨
27.20
買値
25.88
売値
27.30
出来高
205
0.00 日の範囲 0.00
22.9291 52 週間の範囲 53.18
時価総額
1.805B
前日終値
26.58
始値
-
時刻
1
@
27.19
最終取引時間
22:35:54
財務取引量
-
VWAP
-
平均取引量 (3 か月)
1,000,700
発行済株式数
66,344,236
配当利回り
-
PER
-12.47
1 株当たり利益 (EPS)
-2.13
歳入
6.88M
純利益
-141.43M

Celldex Therapeutics Inc について

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung c... Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527. 詳細を表示

セクター
In Vitro,in Vivo Diagnostics
業界
In Vitro,in Vivo Diagnostics
ウェブサイト
www.celldex.com
本社
Wilmington, Delaware, USA
設立
-
Celldex Therapeutics Inc is listed in the In Vitro,in Vivo Diagnostics sector of the ナスダック市場 with ticker CLDX. The last closing price for Celldex Therapeutics was US$26.58. Over the last year, Celldex Therapeutics shares have traded in a share price range of US$ 22.9291 to US$ 53.18.

Celldex Therapeutics currently has 66,344,236 shares in issue. The market capitalisation of Celldex Therapeutics is US$1.76 billion. Celldex Therapeutics has a price to earnings ratio (PE ratio) of -12.47.

Celldex Therapeutics (CLDX) のオプションフロー概要

オプションフロー全体を表示

全体の流れ

ベアリッシュ

ネットプレミアム

-213k

Calls / Puts

0.00%

買い / 売り

100.00%

OTM / ITM

0.00%

Sweeps比率

0.00%

CLDX 最新ニュース

その他のニュース

Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis

HAMPTON, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the Company has initiated a Phase 2 study of barzolvolimab in atopic dermatitis...

2024年12月19日
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

2024年11月21日
Edgar (US Regulatory)

Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

HAMPTON, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company’s Phase 1a study of CDX-622 in...

2024年11月20日
GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

2024年11月15日
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

2024年11月15日
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

2024年11月14日
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

2024年11月14日
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

2024年11月12日
Edgar (US Regulatory)

Celldex Therapeutics to Present at Upcoming Investor Conferences

HAMPTON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:...

2024年11月12日
GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

2024年11月9日
Edgar (US Regulatory)
期間 †前日比前日比 %始値高値安値平均出来高VWAP
11.847.2555205047325.3627.224.55102493526.34791171CS
40.642.4096385542226.5627.2323.9491668925.79445039CS
12-3.09-10.201386596230.2930.4822.9291100070026.47862981CS
26-8.73-24.297244642435.934722.929196936132.05979897CS
52-11.8-30.25641025643953.1822.929189333035.98178037CS
156-8.73-24.297244642435.9353.1819.8569255633.86293703CS
26024.59942.145593872.6157.21.576060327.03629611CS

CLDX - Frequently Asked Questions (FAQ)

What is the current Celldex Therapeutics share price?
The current share price of Celldex Therapeutics is US$ 27.20
How many Celldex Therapeutics shares are in issue?
Celldex Therapeutics has 66,344,236 shares in issue
What is the market cap of Celldex Therapeutics?
The market capitalisation of Celldex Therapeutics is USD 1.76B
What is the 1 year trading range for Celldex Therapeutics share price?
Celldex Therapeutics has traded in the range of US$ 22.9291 to US$ 53.18 during the past year
What is the PE ratio of Celldex Therapeutics?
The price to earnings ratio of Celldex Therapeutics is -12.47
What is the cash to sales ratio of Celldex Therapeutics?
The cash to sales ratio of Celldex Therapeutics is 256.32
What is the reporting currency for Celldex Therapeutics?
Celldex Therapeutics reports financial results in USD
What is the latest annual turnover for Celldex Therapeutics?
The latest annual turnover of Celldex Therapeutics is USD 6.88M
What is the latest annual profit for Celldex Therapeutics?
The latest annual profit of Celldex Therapeutics is USD -141.43M
What is the registered address of Celldex Therapeutics?
The registered address for Celldex Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Celldex Therapeutics website address?
The website address for Celldex Therapeutics is www.celldex.com
Which industry sector does Celldex Therapeutics operate in?
Celldex Therapeutics operates in the IN VITRO,IN VIVO DIAGNOSTICS sector

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
XTIAXTI Aerospace Inc
US$ 0.1918
(117.95%)
623.32M
HOTHHoth Therapeutics Inc
US$ 1.63
(98.88%)
27.61M
IMRXImmuneering Corporation
US$ 4.47
(89.41%)
43.96M
RIMEAlgorhythm Holdings Inc
US$ 0.2552
(76.24%)
183.8M
MSAIMultiSensor AI Holdings Inc
US$ 3.40
(70.00%)
38.63M
LFWDLifeward Ltd
US$ 1.88
(-38.16%)
621.7k
SLRNACELYRIN Inc
US$ 2.295
(-34.24%)
624.42k
AMSTAmesite Inc
US$ 2.79
(-31.11%)
73.94k
BOXLBoxlight Corporation
US$ 1.23
(-26.79%)
1.85M
SRZNSurrozen Inc
US$ 11.01
(-22.63%)
7
XTIAXTI Aerospace Inc
US$ 0.1919
(118.07%)
623.49M
RIMEAlgorhythm Holdings Inc
US$ 0.2552
(76.24%)
183.81M
SVMHSRIVARU Holding Ltd
US$ 0.0659
(42.33%)
126.73M
CDTConduit Pharmaceuticals Inc
US$ 0.11
(52.14%)
75.72M
CEROCERo Therapeutics Holdings Inc
US$ 0.062
(46.57%)
67.21M

CLDX Discussion

投稿を表示

最近閲覧した銘柄

NASDAQ
CLDX
Celldex Therapeutics
NASDAQ
NKBS
Newtek Business Services
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有